Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caicun Zhou

Showing results (11-20 of 550) with videos related to

Pageof 55
Sort By:
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 5, 2015
[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer]Tao Jiang, Caicun Zhou
Scientific Reports|July 5, 2017
Comparison of laboratory testing methods for the diagnosis of tuberculous pleurisy in ChinaQing Zhang, Caicun Zhou
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|November 19, 2014
[Research progress of targeted therapy in non-small cell lung cancer brain metastases]Tao Jiang, Caicun Zhou
Oncotarget|December 17, 2017
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancerXuefei Li, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
Notch Mutations as a Novel Biomarker for ImmunotherapyFei Zhou, Caicun Zhou
The Lancet. Oncology|February 22, 2015
Necitumumab for patients with non-squamous NSCLC: uninspiring resultsFei Zhou, Caicun Zhou
Translational Lung Cancer Research|July 25, 2015
The past, present and future of immunotherapy against tumorTao Jiang, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: ReplyFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a SprintFei Zhou, Caicun Zhou
Cancer Biomarkers : Section a of Disease Markers|January 21, 2014
Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancerLixia Ju, Caicun Zhou
Pageof 55

Showing results (11-20 of 550) with videos related to

Sort By:
Pageof 55
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 5, 2015
[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer]Tao Jiang, Caicun Zhou
Scientific Reports|July 5, 2017
Comparison of laboratory testing methods for the diagnosis of tuberculous pleurisy in ChinaQing Zhang, Caicun Zhou
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|November 19, 2014
[Research progress of targeted therapy in non-small cell lung cancer brain metastases]Tao Jiang, Caicun Zhou
Oncotarget|December 17, 2017
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancerXuefei Li, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
Notch Mutations as a Novel Biomarker for ImmunotherapyFei Zhou, Caicun Zhou
The Lancet. Oncology|February 22, 2015
Necitumumab for patients with non-squamous NSCLC: uninspiring resultsFei Zhou, Caicun Zhou
Translational Lung Cancer Research|July 25, 2015
The past, present and future of immunotherapy against tumorTao Jiang, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: ReplyFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a SprintFei Zhou, Caicun Zhou
Cancer Biomarkers : Section a of Disease Markers|January 21, 2014
Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancerLixia Ju, Caicun Zhou
Pageof 55